Lyell Immunopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Lyell Immunopharma, Inc. (LYEL) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $17.09 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-03-12
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $17.09M.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $1.48M.
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $3.50M.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $3.70M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2025-12-31 | $17.09M 10-K · filed 2026-03-12 |
| 2024-12-31 | $1.48M 10-K · filed 2026-03-12 |
| 2024-09-30 | $3.50M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $3.70M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $8.29M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $7.37M 10-K · filed 2025-03-11 |
| 2023-09-30 | $7.52M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $26.40M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $17.48M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $24.89M 10-K · filed 2024-02-28 |
| 2022-09-30 | $120.30M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $90.97M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $51.89M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $142.08M 10-K · filed 2023-02-28 |
| 2020-12-31 | $100.22M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |